The University of Louisville proposes to establish a Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPMBEID). Our long-term objective is to support the development of gene-based countermeasures and diagnostic approaches based on system changes that occur during host-pathogen interactions. Focusing on host-based bio-threat and emerging infectious disease research should allow the development of broad-spectrum interventions to infectious agents rather than the current paradigm of """"""""one bug/one vaccine"""""""" approach so prevalent today.
Our specific aims are to 1) meet the expanding needs of current researchers who work with Category A, B, or C priority pathogens at the University of Louisville; 2) expand facilities so that we can add an additional six faculty investigators who work with these agents; 3) assemble a unique mix of technologies in a free standing BSL3 facility so that the instrumentation and expertise is available on site to manipulate experimental materials and avoid the need for shipping material off site; and 4) to serve as a resource for investigators from other institutions in our region who can benefit from the unique mix of technologies we will assemble in the facility as well as be prepared to bring those technologies to bear in the event of a bioterrorism emergency. The University created a superb team of investigators and administrators to shepherd this project from application to operation. We are committed to working with NIAID and believe our missions can be mutually reinforced by building a RBL in Louisville.
